Home › Research › Risk factors
High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature
Ouanes S, Popp J.. Frontiers in aging neuroscience, 2019-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Clinical studies found that elevated cortisol was associated with poorer overall cognitive functioning, as well as with poorer episodic memory, executive functioning, language, spatial memory, processing speed, and social cognition; while in animals, glucocorticoid administration resulted in cognitive impairment and abnormal behavior. In cognitively healthy subjects, higher cortisol levels have been associated with an increased risk of cognitive decline and AD. Subjects with dementia and Mild Cognitive Impairment (MCI) due to AD have been found to have higher CSF cortisol levels than cognitively healthy controls. Elevated CSF cortisol may also be associated with a more rapid cognitive decline in MCI due to AD. Elevated cortisol levels have been also found in delirium. High cortisol may mediate the impact of stressful life events, high neuroticism, depression, sleep disturbances, as well as cardiovascular risk factors on cognitive performance, neurodegeneration, and cognitive decline. High cortisol may also exert neurotoxic effects on the hippocampus, and promote oxidative stress and amyloid β peptide toxicity. Further possible underlying mechanisms include the interactions of cortisol with inflammatory mediators, neurotransmitters, and growth factors. Elevated cortisol levels may exert detrimental effects on cognition and contribute to AD pathology. Further studies are needed to investigate cortisol-reducing and glucocorticoidreceptor modulating interventions to prevent cognitive decline.
What this study adds
Evidence grade: Low
This is a narrative review. This review reports that higher cortisol levels are associated with poorer cognitive function and increased risk of cognitive decline and Alzheimer's disease, and may contribute to Alzheimer's pathology. It calls for further studies and does not show that lowering cortisol treats or prevents Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ouanes, S., & Popp, J. (2019). High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature. Frontiers in aging neuroscience. https://doi.org/10.3389/fnagi.2019.00043
Vancouver
Ouanes S, Popp J. High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature. Frontiers in aging neuroscience. 2019. doi:10.3389/fnagi.2019.00043. PMID: 30881301.
BibTeX
@article{ouanes2019-30881301,
author = {Ouanes, S. and Popp, J.},
title = {{High Cortisol and the Risk of Dementia and Alzheimer's Disease: A Review of the Literature}},
journal = {Frontiers in aging neuroscience},
year = {2019},
doi = {10.3389/fnagi.2019.00043},
pmid = {30881301},
url = {https://doi.org/10.3389/fnagi.2019.00043}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Clinical studies found that elevated cortisol was associated with poorer overall cognitive functioning, as well as with poorer episodic memory, executive functioning, language, spatial memory, processing speed, and social cognition; while in animals, glucocorticoid administration resulted in cognitive impairment and abnormal behavior.
- In cognitively healthy subjects, higher cortisol levels have been associated with an increased risk of cognitive decline and AD.
- Subjects with dementia and Mild Cognitive Impairment (MCI) due to AD have been found to have higher CSF cortisol levels than cognitively healthy controls.
- Elevated CSF cortisol may also be associated with a more rapid cognitive decline in MCI due to AD.
- Elevated cortisol levels have been also found in delirium.
Why it matters
This review reports that higher cortisol levels are associated with poorer cognitive function and increased risk of cognitive decline and Alzheimer's disease, and may contribute to Alzheimer's pathology. It calls for further studies and does not show that lowering cortisol treats or prevents Alzheimer's disease.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Evidence strengthLow
How this study scored 53/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Frontiers in aging neuroscience) |
| Journal's citation record | 2 / 4 | Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 472 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 52.4 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 5 / 6 | Cited 30.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 4 / 4 | Cited 213 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Julius Popp: h-index 59 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Centre Hospitalier Universitaire Vaudois: institution h-index 806 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30881301) |
| Free to read | 2 / 2 | Free to read |
| Total | 53 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.3389/fnagi.2019.00043
- PubMed: 30881301
- Original source →
- Free full text: Frontiers in Aging Neuroscience →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Risk factors from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.